CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Percutaneous Electrical Nerve Field Stimulator System (IB-Stim) for Functional Abdominal Pain Disorders

Policy governs medical necessity and coverage for the IB-Stim percutaneous electrical nerve field stimulator for pediatric patients (ages 11-18) with Rome IV-defined functional gastrointestinal disorders, for Medicare Advantage and Commercial products of Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyPercutaneous Electrical Nerve Field Stimulator System (IB-Stim) for Functional Abdominal Pain Disorders

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJan 1, 2025

Next Review DateJan 1, 2025

Key ActionObtain prior authorization for Medicare Advantage members and verify benefits; document eligibility per the member's benefit booklet.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

11-18age range covered

>=9 momin symptom duration

3 classesrequired medication trials

0720TCPT code

5-day

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Medical necessity criteria

Covered when ALL of the following are met:

Eligibility criteria for medical necessity (Medicare Advantage and Commercial)

Age: Patient is between 11 and 18 years of age.
Diagnosis: Diagnosed with a ROME IV-defined functional gastrointestinal disorder (includes functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, or abdominal migraine).
Rule-out of organic disease: Organic gastrointestinal disease has been ruled out.
Symptom duration: Gastrointestinal symptoms have been present for at least 9 months.
Prior therapies
- Medication category A: Acid suppression (H2-blockers or proton pump inhibitors).
- Medication category B: Antispasmodics or motility medications (examples: hyoscyamine, dicyclomine, erythromycin, linaclotide, prucalopride).
- Medication category C: Neuromodulators (examples: amitriptyline, nortriptyline, gabapentin, periactin, aprepitant).
Contraindications / exclusions: No history of cardiac pacemaker, hemophilia, or psoriasis vulgaris.

Individuals with a history of a cardiac pacemaker, hemophilia, or psoriasis vulgaris are excluded from eligibility for IB-Stim per the medical necessity criteria.

All other uses of the percutaneous electrical nerve field stimulator system (IB-Stim) that do not meet the specified medical necessity criteria are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.

Billing and Coding

Covered CPT CodesCPTCovered

0720T

Percutaneous electrical nerve field stimulation, cranial nerves, without implantation

Symptom duration threshold

Minimum symptom durationGI symptoms present for at least 9 months

Applies toChildren and adolescents aged 11-18 years

Context in criteriaRequired element in the medical necessity AND logic for IB‑Stim coverage

Provider Requirements and Operational Notes

Prior Authorization

Prior authorization required for IB-Stim (CPT 0720T)

Prior authorization is required for IB-Stim (CPT 0720T) for Medicare Advantage Plans; prior authorization is recommended for Commercial Products.

Procedure code: 0720T

Step Therapy

Required prior medication trials (3 classes)

Medical necessity requires documented failure of at least one medication from each of three classes, in addition to diet modification, before IB-Stim is considered.

Acid suppression (H2-blockers or PPIs)
Antispasmodics or motility medications (hyoscyamine, dicyclomine, erythromycin/linaclotide, prucalopride)
Neuromodulators (amitriptyline, nortriptyline, gabapentin, periactin, aprepitant)

Background and Clinical Context

Pediatric abdominal pain–related functional gastrointestinal disorders (FAPDs) encompass conditions such as functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, and abdominal migraine. The IB‑Stim is a percutaneous electrical nerve field stimulator intended for children and adolescents aged 11–18 years diagnosed with a ROME IV–defined functional GI disorder when organic disease has been ruled out, symptoms have persisted for at least 9 months, and required medication and diet trials have failed per the policy criteria.

Definitions

IB‑Stim (PENFS) key facts

Device name / typeIB‑Stim — percutaneous electrical nerve field stimulator (PENFS)

MechanismSends gentle electrical impulses to cranial nerve bundles in the external ear to modulate central pain pathways

Typical treatment regimen5‑day device (120 hours) typically worn over 3 consecutive weeks

FDA statusFDA‑cleared auricular device (Neuro‑Stim/IB‑Stim)

Rome IV–defined functional gastrointestinal disorder

Definition (Rome IV)Includes functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome (IBS), functional dyspepsia, and abdominal migraine.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyPercutaneous Electrical Nerve Field Stimulator System (IB-Stim) for Functional Abdominal Pain Disorders

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJan 1, 2025

Next Review DateJan 1, 2025

Key ActionObtain prior authorization for Medicare Advantage members and verify benefits; document eligibility per the member's benefit booklet.

SourceLink

On This Page

Documentation Required

Verify benefits and obtain prior authorization

Verify member benefits and obtain prior authorization as required for Medicare Advantage (recommended for Commercial); document eligibility per the member's Benefit Booklet or Evidence of Coverage.

Confirm coverage details in the Benefit Booklet, Evidence of Coverage, or Subscriber Agreement
Obtain prior authorization for Medicare Advantage; consider prior authorization for Commercial

Denial Risk

Coverage contingent on meeting all listed criteria

Coverage is contingent on meeting all listed medical necessity criteria; use that does not meet these criteria is not covered for Medicare Advantage and not medically necessary for Commercial Products.

All criteria must be met: age 11–18, ROME IV diagnosis, organic GI disease ruled out, ≥9 months of symptoms, required medication trials plus diet modification, and no history of cardiac pacemaker, hemophilia, or psoriasis vulgaris
If any criterion is not met, the IB-Stim is not covered/not medically necessary

Clinical characterization

Group of GI disorders with symptoms not attributable to another condition and with pain as the driving complaint.

Population impactChildren with these disorders have higher disability scores and worse quality of life than peers.